Alzheimer’s and Parkinson’s Diseases: Advances, Concepts and New Challenges

10th International Conference AD/PD
Barcelona, Spain, March 9–13, 2011

PROCEEDINGS

Guest Editors
Roger M. Nitsch, Switzerland
Abraham Fisher, Israel
Manfred Windisch, Austria
Israel Hanin, USA

105 figures, 6 in color, and 33 tables, 2012
Disclaimer
The statements, opinions and data contained in this publica-
tion are solely those of the individual authors and contributors
and not of the publisher and the editor(s). The appearance of
advertisements in the journal is not a warranty, endorsement,
or approval of the products or services advertised or of their
effectiveness, quality or safety. The publisher and the editor(s)
disclaim responsibility for any injury to persons or property
resulting from any ideas, methods, instructions or products
referred to in the content or advertisements.

Drug Dosage
The authors and the publisher have exerted every effort to en-
sure that drug selection and dosage set forth in this text are in
accord with current recommendations and practice at the time
of publication. However, in view of ongoing research, changes
in government regulations, and the constant flow of informa-
tion relating to drug therapy and drug reactions, the reader is
urged to check the package insert for each drug for any change
in indications and dosage and for added warnings and precau-
tions. This is particularly important when the recommended
agent is a new and/or infrequently employed drug.

All rights reserved.
No part of this publication may be translated into other
languages, reproduced or utilized in any form or by any means,
electronic or mechanical, including photocopying, recording,
microcopying, or by any information storage and retrieval
system, without permission in writing from the publisher or,
in the case of photocopying, direct payment of a specified fee to
the Copyright Clearance Center (see ‘General Information’).

© Copyright 2012 by S. Karger AG,
P.O. Box, CH–4009 Basel (Switzerland)
Printed in Switzerland
on acid-free and non-aging paper (ISO 9706) by
Reinhardt Druck, Basel
Nobel Lecture
7 Intracellular Protein Degradation: From a Vague Idea through the Lysosome and the Ubiquitin-Proteasome System and onto Human Diseases and Drug Targeting
Ciechanover, A. (Haifa)

Biology of Neurodegeneration
23 Wnt-5a Is a Synaptogenic Factor with Neuroprotective Properties against Aβ Toxicity
Varela-Nallar, L.; Parodi, J.; Farias, G.G.; Inestrosa, N.C. (Santiago)

27 The Role of S100a9 in the Pathogenesis of Alzheimer’s Disease: The Therapeutic Effects of S100a9 Knockdown or Knockout
Chang, K.-A.; Kim, H.J.; Suh, Y.-H. (Seoul)

30 Inhibition of Amyloid Precursor Protein Beta-Secretase Cleavage Site Affects Survival and Motor Functions of Amyotrophic Lateral Sclerosis Transgenic Mice
Rabinovich-Toidman, P.; Becker, M.; Barbiro, B.; Solomon, B. (Tel Aviv)

34 The Antioxidant N-Acetylcysteine Prevents the Mitochondrial Fragmentation Induced by Soluble Amyloid-β Peptide Oligomers

38 Mitochondrial Metabolic Control of Microtubule Dynamics Impairs the Autophagic Pathway in Parkinson’s Disease
Cardoso, S.M.; Esteves, A.R.; Arduino, D.M. (Coimbra)

41 The Effects of Apolipoproteins E3 and E4 on the Transforming Growth Factor-β System in Targeted Replacement Mice
Haas, A.; Liraz, O.; Michaelson, D.M. (Tel Aviv)

46 Protein Kinase Activity Profiling of Postmortem Human Brain Tissue
Hoozemans, J.J.M. (Amsterdam); Hilhorst, R.; Ruijtenbeek, R. (S-Hertogenbosch); Rozemuller, A.J.M.; van der Vies, S.M. (Amsterdam)

49 Parkin: Much More than a Simple Ubiquitin Ligase
Alves da Costa, C.; Checler, F. (Valbonne)

52 p53, a Pivotal Effector of a Functional Cross-Talk Linking Presenilins and Pen-2
Checler, F.; Dunys, J. (Valbonne)

56 Intraneuronal Aβ Accumulation, Amyloid Plaques, and Synapse Pathology in Alzheimer’s Disease
Capetillo-Zarate, E.; Gracia, L. (New York, N.Y.); Tampellini, D. (Lund); Gouras, G.K. (New York, N.Y./Lund)

60 A Persistent Stress Response to Impeded Axonal Transport Leads to Accumulation of Amyloid-β in the Endoplasmic Reticulum, and Is a Probable Cause of Sporadic Alzheimer’s Disease
Muresan, V.; Muresan, Z. (Newark, N.J.)

64 Linking Amyloid-β and Tau: Amyloid-β Induced Synaptic Dysfunction via Local Wreckage of the Neuronal Cytoskeleton
Zempel, H.; Mandelkow, E.-M. (Hamburg/Bonn)

73 Tau Overexpression Results in Its Secretion via Membrane Vesicles
Simón, D.; García-García, E.; Gómez-Ramos, A. (Madrid); Falcón-Pérez, J.M. (Derio); Diaz-Hernández, M.; Hernández, F.; Avila, J. (Madrid)

76 Dysregulation of Ca²⁺ Homeostasis in Alzheimer’s Disease: Role in Acetylcholinesterase Production and AMPA Receptor Internalization
Small, D.H. (Hobart, Tas.)
80 Cyclin D1 Induction Preceding Neuronal Death via the Excitotoxic NMDA Pathway Involves Selective Stimulation of Extrasynaptic NMDA Receptors and JNK Pathway
Efthimiadi, L. (Marseille); Farso, M.; Quirion, R. (Montréal, Que.); Krantic, S. (Marseille/Montréal, Que.)

92 Contribution of Kunitz Protease Inhibitor and Transmembrane Domains to Amyloid Precursor Protein Homodimerization
Ben Khalifa, N.; Tyteca, D.; Courtoy, P.J.; Renaud, J.C.; Constantinescu, S.N.; Octave, J.N.; Kienlen-Campard, P. (Brussels)

96 Expanding the Multipotent Profile of Huprine-Tacrine Heterodimers as Disease-Modifying Anti-Alzheimer Agents
Muñoz-Torrero, D.; Pera, M.; Relat, J.; Ratia, M.; Galdeano, C.; Viayna, E.; Sola, I.; Formosa, X.; Camps, P.; Badia, A.; Clos, M.V. (Barcelona)

100 Microglial Activation in Neuroinflammation: Implications for the Etiology of Neurodegeneration
Kaneko, Y.S.; Nakashima, A.; Mori, K.; Nagatsu, T.; Nagatsu, I.; Ota, A. (Toyoake)

104 Preplaque (‘Preclinical’) Aβ-Induced Inflammation and Nerve Growth Factor Deregulation in Transgenic Models of Alzheimer’s Disease-Like Amyloid Pathology
Cuello, A.C.; Ferretti, M.T.; Iulita, M.F. (Montreal, Que.)

108 Clearance of Amyloid-β Protein Deposits in Transgenic Mice following Focal Cerebral Ischemia
Van Nostrand, W.E.; Davis, J.; Previti, M.L.; Xu, F. (Stony Brook, N.Y.)

112 Novel Therapeutic Approach for Neurodegenerative Pathologies: Multitarget Iron-Chelating Drugs Regulating Hypoxia-Inducible Factor 1 Signal Transduction Pathway
Weinreb, O.; Amit, T.; Mandel, S.; Youdim, M.B.H. (Haifa)

116 Retromers in Alzheimer’s Disease
Siegenthaler, B.M.; Rajendran, L. (Zurich)

122 APOE-Mimetic Peptides Reduce Behavioral Deficits, Plaques and Tangles in Alzheimer’s Disease Transgenics
Vitek, M.P. (Research Triangle Park, N.C./Durham, N.C.); Christensen, D.J. (Research Triangle Park, N.C.); Wilcock, D. (Durham, N.C.); Davis, J.; Van Nostrand, W.E. (Stony Brook, N.Y.); Li, F.Q. (Research Triangle Park, N.C.); Colton, C.A. (Durham, N.C.)

Clinical Studies and Observations

127 Effects of Exercise and B Vitamins on Homocysteine and Glutathione in Parkinson’s Disease: A Randomized Trial
DiFrancisco-Donoghue, J. (Old Westbury, N.Y.); Lamberg, E.M. (Stony Brook, N.Y.); Rabin, E. (Old Westbury, N.Y.); Elekda, A. (Cairo); Fazzini, E.; Werner, W.G. (Old Westbury, N.Y.)

135 Association of Cardiorespiratory Fitness and Morphological Brain Changes in the Elderly: Results of the Austrian Stroke Prevention Study

138 Evaluation of the Performance of Novel Aβ Isoforms as Theragnostic Markers in Alzheimer’s Disease: From the Cell to the Patient
Portelius, E.; Gustavsson, M.K.; Zetterberg, H.; Andreasson, U.; Blennow, K. (Mölndal)

141 Relationship between Memory Performance and β-Amyloid Deposition at Different Stages of Alzheimer’s Disease

145 Apolipoprotein E4 and Brain White Matter Integrity in Alzheimer’s Disease: Tract-Based Spatial Statistics Study under 3-Tesla MRI

149 Software Tool for Improved Prediction of Alzheimer’s Disease
Soininen, H. (Kuopio); Mattila, J.; Koikkalainen, J.; van Gils, M. (Tampere); Hvid Simonsen, A.; Waldemar, G. (Copenhagen); Ruckert, D. (London); Thrurflott, L. (Uppsala); Lötingen, J. (Tampere) for the Alzheimer’s Disease Neuroimaging Initiative

153 From Morris Water Maze to Computer Tests in the Prediction of Alzheimer’s Disease
Laczó, J. (Brno/Prague); Andel, R. (Brno/Tampa, Fla.); Vyhnalek, M.; Vlcek, K. (Brno/Prague); Magerova, H.; Varjassovyo, A. (Prague); Nedelska, Z.; Gazova, I. (Brno/Prague); Bojar, M. (Prague); Sheardova, K. (Brno); Hort, J. (Brno/Prague)

158 Identifying Earlier Alzheimer’s Disease: Insights from the Preclinical and Prodromal Phases
Molinuevo, J.L.; Sánchez-Valle, R.; Lladó, A.; Fortea, J.; Bartrés-Faz, D.; Rami, L. (Barcelona)

161 Differential Diagnosis in Alzheimer’s Disease and Dementia with Lewy Bodies via VMAT2 and Amyloid Imaging
Immunization and Innate Immunity

261 Delivery of a DNA Vaccine for Alzheimer’s Disease by Electroporation versus Gene Gun Generates Potent and Similar Immune Responses
Davtyan, H. (Huntington Beach, Calif./Irvine, Calif.); Ghochikyan, A. (Huntington Beach, Calif.); Movsesyan, N. (Irvine, Calif.); Ellefsen, B. (San Diego, Calif.); Petrushina, I.; Cribbs, D.H. (Irvine, Calif.); Hannaman, D.; Evans, C.F. (San Diego, Calif.); Agadjanyan, M.G. (Huntington Beach, Calif./Irvine, Calif.)

265 Passive Immunization against Pyroglutamate-3 Amyloid-β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study
Frost, J.L.; Liu, B. (Boston, Mass.); Kleinschmidt, M.; Schilling, S.; Demuth, H.-U. (Halle (Saale)); Lemere, C.A. (Boston, Mass.)

271 Innate Immunity and the Etiology of Late-Onset Alzheimer’s Disease

274 Curcumins Promote Monocytic Gene Expression Related to β-Amyloid and Superoxide Dismutase Clearance
Cashman, J.R. (San Diego, Calif.); Gagliardi, S. (Pavia); Lanier, M.; Ghirmai, S.; Abel, K.J. (San Diego, Calif.); Fiala, M. (Los Angeles, Calif.)

277 Subsequent Risks of Parkinson Disease in Patients with Autoimmune and Related Disorders: A Nationwide Epidemiological Study from Sweden
Li, X. (Malmö); Sundquist, J. (Malmö/Stanford, Calif.); Sundquist, K. (Malmö)

285 Alzheimer’s Disease in the Retina: Imaging Retinal Aβ Plaques for Early Diagnosis and Therapy Assessment
Koronyo, Y.; Salumbides, B.C.; Black, K.L.; Koronyo-Hamaoui, M. (Los Angeles, Calif.)

Prion Proteins, Statins, Cholesterol

294 α-Secretase-Derived Cleavage of Cellular Prion Yields Biologically Active Catabolites with Distinct Functions
Guillot-Sestier, M.-V.; Checler, F. (Valbonne)

298 Cellular Prion Protein Mediates Toxic Signaling of Amyloid Beta
Resenberger, U.K.; Winklhofer, K.F.; Tatzelt, J. (Munich)

301 Neuroinflammation and Common Mechanism in Alzheimer’s Disease and Prion Amyloidosis: Amyloid-Associated Proteins, Neuroinflammation and Neurofibrillar Degeneration

305 Dual Effects of Statins on Aβ Metabolism: Upregulation of the Degradation of APP-CTF and Aβ Clearance
Sato, N.; Shinohara, M.; Rakugi, H.; Morishita, R. (Suita)

309 Statins in Unconventional Secretion of Insulin-Degrading Enzyme and Degradation of the Amyloid-β Peptide
Glebov, K.; Walter, J. (Bonn)

313 Side-Chain-Oxidized Oxyesters Upregulate ACE2 and Mas Receptor in Rat Primary Neurons

Cerebrovascular Lesions and Primary Neurodegenerative Diseases

317 Tissue Transglutaminase: A Novel Therapeutic Target in Cerebral Amyloid Angiopathy
Wilhelmus, M.M.M.; de Jager, M.; Drukarch, B. (Amsterdam)

320 Plasma β-Amyloid Levels in Cerebral Amyloid Angiopathy-Associated Hemorrhagic Stroke

324 Insights into Caspase-Mediated Apoptotic Pathways Induced by Amyloid-β in Cerebral Microvascular Endothelial Cells
Fossati, S.; Ghiso, J.; Rostagno, A. (New York, N.Y.)

329 Neuroinflammation and Blood-Brain Barrier Changes in Capillary Amyloid Angiopathy

332 Author Index
335 Subject Index